Moliya
Moliya
Bosh sahifaDRREDDY • NSE
Dr Reddy's Laboratories Ltd
1 197,50 ₹
4-noy, 15:59:52 (GMT+5:30) · INR · NSE · Ogohlantirish
AksiyalarIN qimmatli qogʻoziBosh shtabi: IN
Yopilish kursi
1 196,00 ₹
Kunlik diapazon
1 193,30 ₹ - 1 204,30 ₹
Yillik diapazon
1 020,00 ₹ - 1 405,90 ₹
Bozor kapitalizatsiyasi
998,63 mlrd INR
Oʻrtacha hajm
2,06 mln
Narx/foyda
17,30
Dividend daromadliligi
0,67%
Asosiy maydon
NSE
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(INR)sen, 2025Y/Y qiyosi
Daromad
88,05 mlrd9,84%
Joriy xarajat
31,90 mlrd7,31%
Sof foyda
14,37 mlrd14,49%
Sof foyda marjasi
16,324,21%
Har bir ulushga tushum
17,8712,91%
EBITDA
21,29 mlrd-3,30%
Amaldagi soliq stavkasi
22,25%
Jami aktivlari
Jami passivlari
(INR)sen, 2025Y/Y qiyosi
Naqd pul va qisqa investitsiyalar
69,81 mlrd10,68%
Jami aktivlari
542,00 mlrd16,32%
Jami passivlari
179,92 mlrd14,84%
Umumiy kapital
362,08 mlrd
Tarqatilgan aksiyalar
832,52 mln
Narxi/balansdagi bahosi
2,78
Aktivlardan daromad
7,65%
Kapitaldan daromad
9,87%
Naqd pulning sof oʻzgarishi
(INR)sen, 2025Y/Y qiyosi
Sof foyda
14,37 mlrd14,49%
Operatsiyalardan naqd pul
15,57 mlrd67,16%
Sarmoyadan naqd pul
-9,54 mlrd49,96%
Moliyadan naqd pul
-5,32 mlrd-132,96%
Naqd pulning sof oʻzgarishi
902,00 mln-85,84%
Boʻsh pul
3,25 mlrd-17,00%
Haqida
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
Tashkil etilgan
1984
Xodimlar soni
27 811
Yana
Bu sizni qiziqtirishi mumkin
Bu roʻyxat oxirgi qidiruvlar, kuzatilgan aksiyalar va boshqa faoliyatdan tuzilgan. Batafsil

Barcha axborotlar faqat maʼlumot sifatida “shundayligicha” taqdim etilgan, ulardan moliyaviy maslahat sifatida foydalanmang, ular savdo maqsadlari yoki investitsiya, soliq, yuridik, buxgalteriya yoki boshqa turdagi maslahat emas. Google investitsiya borasida maslahatchi emas, bu roʻyxatdagi kompaniyalar yoki ularning aksiyalari borasida hech qanday nuqtai nazar, tavsiya yoki fikr bildirmaydi. Har qanday savdoni boshlashdan oldin broker yoki moliyaviy vakil bilan maslahatlashib, narxlarni tekshiring. Batafsil
Aloqador qidiruvlar
Qidiruv
Qidiruv maydonini tozalash
Qidiruvni yopish
Google ilovalari
Asosiy menyu